Ratings Bangkok Dusit Medical Services Thailand S.E.

Equities

End-of-day quote Thailand S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
27.25 ^THB	-0.91%		-0.91%	-1.80%

05-14	Bangkok Dusit Medical Services Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Bangkok Dusit Medical Services Public Company Limited Announces Appointment of Kongkiat Kespechara as Executive Committee Member	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

The company returns high margins, thereby supporting business profitability.
The company is in a robust financial situation considering its net cash and margin position.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

With a 2024 P/E ratio at 27.04 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
With an enterprise value anticipated at 3.94 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.

	1st Jan change	Capi.	ESG Refinitiv
BANGKOK DUSIT MEDICAL SERVICES	-1.80%	11.9B	-
AIER EYE HOSPITAL GROUP CO., LTD.	-26.36%	15.04B	B+
IHH HEALTHCARE	+3.65%	11.73B	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+8.83%	10.68B	B+
ENCOMPASS HEALTH CORPORATION	+26.35%	8.55B	B
RAMSAY HEALTH CARE LIMITED	-8.21%	7.35B	A-
MOUWASAT MEDICAL SERVICES COMPANY	+9.84%	6.48B	D
FORTIS HEALTHCARE LIMITED	+19.81%	4.36B	B+
DALLAH HEALTHCARE COMPANY	-4.42%	4.28B	-
GLOBAL HEALTH LIMITED	+41.40%	4.11B	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality